Condition: HPV-Related Squamous Cell Carcinoma · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
This description comes directly from the study's public registry record.
Zubair Khan, M.D. · 410-955-3157 · zkhan@jhmi.edu
Sydjea Stillwell, R.N. · 410-614-9231 · sstillw1@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04988074